Studies on Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitory Effects and Enzyme Selectivity of F-1394, a Pantotheic Acid Derivative
Open Access
- 1 January 1995
- journal article
- research article
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 67 (3) , 195-204
- https://doi.org/10.1254/jjp.67.195
Abstract
(1s,2s)-2-[3-(2,2-Dimethylpropyl)-3-nonylureido]aminocyclohe xane-1-yl 3-[N-(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate (F-1394), a pantotheic acid derivative, is a newly synthesized inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). In the present study, we investigated the inhibitory effects of F-1394 on the activities of ACAT. F-1394 reduced the ACAT activities in rat liver microsomes, homogenate of rabbit small intestinal mucosa and lysate of J774 macrophages with IC50 values of 6.4 nM, 10.7 nM and 32 nM, respectively. The kinetic studies showed that F-1394 exerted competitive-type inhibition, and the Ki values in liver and small intestinal ACAT were 4.0 nM and 9.9 nM, respectively. The inhibitory effects of F-1394 on the activity of ACAT were more potent than that of other ACAT inhibitors or hypolipidemic agents. The study on enzyme selectivity indicated that F-1394 did not affect 3-hydroxy-3-methylglutaryl CoA reductase, acyl-CoA synthetase and cholesterol esterase. F-1394 weakly inhibited the activity of lecithine:cholesterol acyltransferase (LCAT) originating from rat plasma. The inhibitory potency of F-1394 for the activity of liver microsomal ACAT was 4,690-fold stronger than that for the activity of LCAT. These findings indicate that F-1394 is a potent and selective inhibitor of ACAT, and its inhibition manner is the competitive type.Keywords
This publication has 13 references indexed in Scilit:
- ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agentsTrends in Pharmacological Sciences, 1991
- Ca++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. I. Characterization of cellular lipid metabolism.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988
- Potential antiatherosclerotic agents. 5. An acyl-coenzyme A:cholesterol O-acyltransferase inhibitor with hypocholesterolemic activityJournal of Medicinal Chemistry, 1986
- Mechanism of the Inhibition of Cholesterol Absorption by DL-Melinamide: Inhibition of Cholesterol EsterificationThe Japanese Journal of Pharmacology, 1986
- 15 Acyl Coenzyme A: Cholesterol O-AcyltransferasePublished by Elsevier ,1983
- Nonoxidative ethanol metabolism: formation of fatty acid ethyl esters by cholesterol esterase.Proceedings of the National Academy of Sciences, 1982
- Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase.Proceedings of the National Academy of Sciences, 1981
- Studies on cholesterol esterase in rat arterial wallAtherosclerosis, 1979
- Inhibition of in vitro cholesterol synthesis by fatty acidsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1977